GT1-7 cells respond to treatment with the phorbol ester, phorbol 12-myristate 13-acetate (PMA), with an inhibition of transcription of the proGnRH gene and decreases in GnRH mRNA levels. However, the timing of this decrease in GnRH mRNA levels suggests that a decrease in GnRH mRNA stability may be involved in addition to an inhibition of transcription of the proGnRH gene. To address this possibility, we treated GT1-7 cells with 100 nM PMA for 4 h and then monitored GnRH mRNA levels over time after blockade of GnRH gene transcription with DRB.
Gonadotropin-releasing hormone (GnRH ) mRNA levels are mRNA levels and decrease translational efficiency of the GnRH mRNA (10) (11) (12) (13) (14) (15) . While the decrease in GnRH gene transcription regulated by numerous neurotransmitters, hormones and growth by phorbol esters occurs quickly, measurements of GnRH mRNA factors (1) (2) (3) (4) (5) (6) . We have previously reported that GnRH mRNA half-life suggest that it is a stable mRNA (t 1/2 >20 h; 15) and it levels in rat brain can be altered by the glutamate analog would take many hours for such transcriptional changes to be N-methyl-D,L-aspartate treatment or during the estrous cycle manifested as changes in mRNA levels. It therefore appears that without concomitant changes in GnRH primary transcript (1, 2) , an additional mechanism, along with decreased transcription, is an index of GnRH gene transcription (7) . We hypothesized that responsible for the decrease in GnRH mRNA levels observed this increase in GnRH mRNA levels, occurring independently of following PMA treatment. Thus, in the present study, we examtranscription, is due to a post-transcriptional change such as an ined whether GnRH mRNA stability is also decreased by PMA enhancement of mRNA stability, i.e. a decrease in degradation treatment in GT1-7 cells. of the existing GnRH mRNA pool. However, because of the small number and widespread distribution of GnRH neurons in the mammalian brain (8) we approached this issue of mRNA stability using the immortalized mouse hypothalamic GnRHsecreting cell line, the GT1 cells (9) . These cells have facilitated
Results

an understanding of how neurotransmitters and other factors
RNase protection assay (Experiment I) affect GnRH secretion and gene expression at a cellular and/or molecular level.
GnRH primary transcript levels measured using the A2B clone Much of the research on GnRH release and gene expression in decreased significantly compared to DMSO controls following the GT1 cell lines has focused on the protein kinase C 3 h PMA treatment (P<0.0001; Fig. 1 ). Levels were still sig-(PKC )/calcium second messenger systems which mediate the nificantly depressed at 10 h PMA treatment (P<0.001), but effects of neurotransmitters (10-13). The phorbol ester, phorbol returned to control levels at 21 h PMA treatment. For GnRH 12-myristate 13-acetate (PMA), a PKC activator, has been mRNA levels in the cytoplasm, a significant decrease was observed beginning 10 h after the initiation of PMA treatment (P<0.0001), reported to inhibit transcription of the proGnRH gene, decrease digested with RNase H migrated in a broader band, as is seen in lanes 8-14.
Neither treatment with PMA nor time affected the size of the RNase H-treated mRNA, and the average size of this 'tailless' GnRH mRNA for all treatment groups, as determined by comparison to RNA and DNA molecular size markers, was approximately 486 bases, which corresponds to the size of the mouse GnRH without a poly ( A) tail (Fig. 4) . For the mRNA which had a poly ( A) tail, the mean size of the GnRH mRNA did not differ among the control groups, and had a mean size of 587 bases ( Fig. 4 ). There was a significant shift in the size distribution of the GnRH mRNA transcript following 4 and 8 h PMA treatment ( P<0.001; Fig. 4 ), to 547 and 524 bases, respectively. The mean size of the GnRH mRNA returned to slightly greater than control levels (606 bases) following 24 h PMA treatment (Fig. 4 ).
Discussion
Two major factors largely determine the levels of a specific mRNA present in a cell: first, the rate of transcription of the gene encoding this RNA, and second, the rate of degradation of this mRNA in the cytoplasm (i.e., mRNA stability). In the present study, we observed that GnRH mRNA levels decreased two-fold after treatment for ten hours with the phorbol ester PMA. In order to estimate the contribution of GnRH gene transcription to levels of GnRH mRNA, we measured levels of GnRH primary transcript in the nucleus. We have observed that changes in GnRH primary transcript parallel transcription of the GnRH gene, as measured by transcription run-on assays ( 7), and thus levels of primary transcript in the nucleus are a good indication of transcriptional activity of the proGnRH gene. In the present study, GnRH primary transcript levels were sig- of the proGnRH gene following PMA treatment using decreased at 3 and 10 h compared to controls. GnRH mRNA levels were transfection/GnRH promoter activity in GT1 cells (7, 13, 15 ) . the decrease in GnRH gene transcription; therefore it is possible that this latter decrease is simply a reflection of the preceding decline in GnRH gene transcription. However, it has been reported in the present and a previous study (15 ) that the halfand levels were even further decreased at 21 h of PMA treatment life of the GnRH mRNA is quite long (>20 h), suggesting that (P<0.0001; Fig. 1 ).
even if transcription of the GnRH gene were completely blocked by PMA treatment, it would take more than 20 h to see a twoDetermination of GnRH mRNA half-life (Experiment II) fold decrease in cytoplasmic GnRH mRNA levels. GnRH mRNA levels were observed to decay with a half-life of We addressed this issue by measuring the half-life of GnRH 30 h in control (DMSO)-treated GT1-7 cells following DRB mRNA in the presence or absence of PMA. This would directly treatment ( Fig. 2 ). When cells were treated with PMA for 4 h determine whether phorbol esters alter GnRH mRNA stability. prior to DRB treatment, the half-life of the GnRH mRNA
In control (DMSO-treatment) GT1-7 cells, we determined GnRH decreased to 11 h (Fig. 2 ). In contrast, cyclophilin mRNA halfmRNA half-life to be 30 h, similar to that (22 h) reported in a life in GT1-7 cells was similar both in the presence ( 14 h) or previous study using the RNA synthesis inhibitor actinomycin D absence (13 h) of PMA (data not shown), indicating that the (15). In the present study, when GT1-7 cells were pre-treated effect of PMA is specific to the GnRH system.
with PMA for 4 h, the half-life decreased to 11 h. In contrast, in another laboratory ( 15), co-treatment of GT1 cells with the Poly (A) tail analysis (Experiment III) phorbol ester and actinomycin D did not significantly change GnRH mRNA half-life ( to 18 h). This lack of effect on GnRH A representative Northern blot demonstrating migration of GnRH mRNA through the agarose gel is shown in Fig. 3 . The mRNA half-life is most likely due to the co-administration of the two drugs in the previous study (15 ), compared to 4 h premRNA that was digested with RNase H is shown in lanes 1-7, and appears as a discrete band. Messenger RNA that was not treatment with PMA in the present study. Treatment with PMA appears to cause an activation of cellular factors that are involved the present study. Our finding supports the hypothesis that PMA has direct effects on GnRH mRNA stability, and it is therefore in degrading the GnRH mRNA, which under basal conditions in GT1 cells has an extremely long half-life (15, 16). When GT1
likely that the rate of turnover of the GnRH mRNA, as well as gene transcription, plays an important role in determining GnRH cells are treated with PMA and an RNA or protein synthesis blocker simultaneously, these cellular factors cannot be induced, mRNA levels. Therefore, in Experiment III we assessed changes in GnRH mRNA stability by measuring changes in GnRH preventing a change in GnRH mRNA turnover rate. Exposure of GT1-7 cells to PMA for 4 h prior to treatment with the RNA mRNA poly ( A) tail length in response to treatment with PMA. Poly (A) tail length has been reported to be an important or protein synthesis inhibitor is sufficient to activate this 'turnover system' ( 16) and thus the factors that are responsible for turning indicator of mRNA stability in numerous systems ( 17, 18). For example, deadenylated rabbit globin mRNA injected into Xenopus over the GnRH mRNA have already been induced and can thus elicit a subsequent decrease in the GnRH mRNA half-life, as in oocytes was found to have a half life of 5-10 h. In contrast, when the mRNA containing the poly (A) tail was injected, it was still ion and globin (30), and in response to changes in the cellular environment such as the steroid hormone milieu (31), lactation not degraded at >48 h (19) . It was reported in yeast cell-free extracts that polyadenylation of the 3∞ end stabilized the mRNA, (29), phorbol esters (32), osmotic condition (24, 26) or stimulation by neurotransmitters (27 ) . Thus, this appears to be an irrespective of the mRNA species (20 ). For the c-fos system, a shortening of the poly (A) tail from~200 to a length of 30-60 important and ubiquitous mechanism for the regulation of mRNA levels. nucleotides was followed by decay of the mRNA, indicating that the decrease in the poly (A) tail length may in fact be causal to
In the present study we found that the average size of the GnRH mRNA poly (A) tail was significantly reduced in GT1-7 the mRNA degradation ( 21). These and other studies (22, 23) have provided strong evidence that a longer poly (A) tail probably cells by treatment with PMA. This most likely represents a decrease in mRNA stability and may contribute to the degradaconfers stability upon the mRNA, while in contrast, poly ( A) tail shortening precedes and may result in degradation of the mRNA.
tion of GnRH mRNA, with a subsequent decrease in GnRH mRNA levels. The GnRH mRNA species containing the poly Furthermore, alterations in poly (A) tail length have been reported in several neuroendocrine and other systems such as (A) tail migrated through the gel in a relatively broad band with an average size of 587 bases as determined by comparison to an vasopressin (24-26), prolactin ( 27) , oxytocin (28, 29), and chor- increased without a concomitant increase in primary transcript (1, 33) . While RNA synthesis inhibitor or pulse-chase studies are
Determination of GnRH mRNA half-life (Experiment II) extremely difficult to perform in vivo, it is possible to measure GT1-7 cells were cultured as above. At t=-4 h, the medium was changed GnRH mRNA poly ( A) tail size in the animal (Gore & Roberts, to DMEM containing PMA ( 100 nM ) or vehicle (DMSO; 35 ). At t= unpublished observation). We hope to apply the techniques used 0 h, cells were treated with 5,6-dichloro-1-b-ribofuranosylbenzimidazole (DRB; 100 mg/ml final concentration). This reversible RNA polymerase in the GT1-7 cell line to these types of animal models in order inhibitor is less toxic than actinomycin D and more specific to the RNA to investigate in a physiological system those mechanisms involved polymerase II system ( 36) . The dose of DRB was chosen based on our in the regulation of GnRH gene expression.
previous observation that it causes a rapid and almost complete disappearance of GnRH primary transcript in GT1-7 cells within 60 min of administration (16), suggesting a rapid blockade of GnRH gene transcription ( 7). This result is similar to the inhibition of RNA synthesis reported
Materials and methods
in primary pituitary cell cultures (37 ) . Cells were harvested at t=0, 1, 2, Cell culture and treatment 4 or 8 h after DRB treatment. Experiments were repeated four times with a similar half-life obtained GT1-7 cells were cultured as described previously ( 14). In Experiments each time; the results presented in Fig. 2 are a representative case. I and II, studies were done in triplicate cultures, and were repeated four Cytoplasmic mRNA was harvested and assayed by RNase protection times. For Experiments III, single dishes were used per treatment, and assay, as described above. The GnRH mRNA half-life was determined experiments were repeated 6 times. Phorbol 12-myristate 13-acetate by performing a regression analysis on the change in GnRH mRNA (PMA; Calbiochem, San Diego, CA; 100 nM) or vehicle (DMSO) was levels for both control and PMA-treated GT1-7 cells. Cyclophilin mRNA added to dishes for 0, 3, 10 or 21 h ( Experiment I ) or 0, 4, 8 or 24 h levels were measured in the same samples by RNase protection assay and ( Experiment III ). Cells were harvested, spun down for 5 min at 800×g, the cyclophilin mRNA half-life was determined in the same manner and the cell pellet resuspended in 400 ml lysis buffer (34) . This fraction was layered over 350 ml cushion buffer and centrifuged at 800×g. The as the GnRH mRNA half-life.
